---
title: 'First effectiveness data of lenvatinib and pembrolizumab as first-line therapy
  in advanced anaplastic thyroid cancer: a retrospective cohort study'
date: '2024-02-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38383419/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240222170805&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The combination of lenvatinib and pembrolizumab was effective
  and moderately tolerated in treatment-naïve ATC patients with occasional long-lasting
  response. However, we could not confirm the exceptional responses for this combination
  therapy reported before in pretreated ...'
disable_comments: true
---
CONCLUSIONS: The combination of lenvatinib and pembrolizumab was effective and moderately tolerated in treatment-naïve ATC patients with occasional long-lasting response. However, we could not confirm the exceptional responses for this combination therapy reported before in pretreated ...